{"nct_id":"NCT03168438","title":"Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma","status":"TERMINATED","status_verified_date":"2021-10","start_date":"2017-08-18","start_date_type":"ACTUAL","primary_completion_date":"2020-07-13","primary_completion_date_type":"ACTUAL","completion_date":"2020-11-05","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["GSK"]}